LyondellBasell
LYB
$73.25
-2.99%
LyondellBasell Industries N.V. is a global petrochemical producer, operating primarily in the United States, Europe, and Asia, within the specialty chemicals industry. The company is a market leader, holding the title of the world's largest producer of polypropylene and a major producer of polyethylene and propylene oxide, with its products serving a wide array of consumer and industrial end markets. The current investor narrative is dominated by a severe industry downturn, evidenced by the company's recent dividend cut, which management attributed to 'one of the longest downturns in the chemical industry,' and near-term pressures from geopolitical supply disruptions in key feedstock like naphtha, creating a debate between the stock's strong technical recovery and persistent fundamental headwinds.…
LYB
LyondellBasell
$73.25
Related headlines
LYB 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on LyondellBasell's 12-month outlook, with a consensus price target around $95.23 and implied upside of +30.0% versus the current price.
Average Target
$95.23
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$59 - $95
Analyst target range
The stock has coverage from 10 analysts, with a consensus that appears cautiously optimistic given the fundamental challenges, as evidenced by recent upgrades from firms like Citigroup and RBC Capital. The average target price implied by the consensus EPS estimate of $5.64 and a forward PE of 15.0 is approximately $84.60, representing a potential upside of about +15% from the current price of $73.72. The target range is wide, with a low EPS estimate of $4.05 and a high of $7.41, implying a price range from roughly $60.75 to $111.15 based on the same forward multiple; the high target assumes a significant recovery in earnings power and multiple expansion, while the low target prices in a continuation of the severe downturn. Recent institutional rating actions show a notable shift, with upgrades from Sell/Underperform to Neutral/Buy by UBS, RBC Capital, and BMO Capital in March 2026, suggesting a growing belief that the worst of the cycle may be priced in.
Bulls vs Bears: LYB Investment Factors
The investment debate for LYB is a classic clash between deep cyclical value and severe near-term fundamental deterioration. The bull case, currently supported by stronger evidence from the powerful price momentum and analyst sentiment shift, hinges on the stock's extreme valuation discount and the market's anticipation of a cyclical inflection. The bear case is grounded in the harsh reality of ongoing losses, margin compression, and a recent dividend cut. The single most important tension is the timing and magnitude of the chemical cycle recovery. If LYB demonstrates even a modest sequential improvement in margins in the next quarter, the bull thesis of re-rating from trough multiples could accelerate. Conversely, another quarter of significant losses or further negative guidance would validate the bear view that the downturn has longer to run, potentially sending the stock back towards its 52-week low.
Bullish
- Deep Cyclical Valuation Discount: LYB trades at a trailing PS ratio of 0.46x and EV/Sales of 1.15x, a substantial discount to typical specialty chemical industry averages above 1.0x Sales. This valuation is near the absolute bottom of its historical range, which has exceeded 3.5x Sales during peak cycles, pricing in extreme pessimism and offering significant upside if the cycle inflects.
- Powerful Technical Momentum & Breakout: The stock is in a sustained uptrend, up 64.15% over six months and 51.34% over three months, dramatically outperforming the S&P 500. Trading at $73.72, it is 76% of the way to its 52-week high of $83.94, signaling a powerful breakout from its prior range and strong investor conviction in a recovery narrative.
- Robust Free Cash Flow Cushion: Despite operating losses, LYB generated $2.26 billion in TTM free cash flow. This strong cash generation provides a crucial buffer to navigate the downturn, fund the reduced dividend, and maintain financial flexibility, as evidenced by a healthy current ratio of 1.77.
- Analyst Upgrades & Consensus Upside: Recent upgrades from major firms (UBS, RBC, BMO) from Sell/Underperform to Neutral/Buy suggest a growing belief the worst is priced in. The consensus average target price implied by a forward PE of 15.0 and EPS of $5.64 is approximately $84.60, offering a +15% upside from the current price.
Bearish
- Severe Industry Downturn & Losses: LYB is in the midst of a severe cyclical downturn, with Q4 2025 revenue down -25.33% YoY to $7.09B and a net loss of -$140M. Gross margin compressed to 6.49% from 7.80% a year prior, reflecting intense margin pressure and the company's description of 'one of the longest downturns in the chemical industry.'
- Dividend Cut Signals Prolonged Weakness: The company's drastic dividend cut, as reported in recent news, is a clear signal of management's expectation for prolonged cash flow challenges. This action removes a key income support for investors and reflects deep fundamental headwinds that could pressure the stock despite technical strength.
- Geopolitical Supply Chain Disruptions: Recent news highlights severe naphtha supply disruptions in the Middle East due to geopolitical conflict, threatening production costs and output. This creates near-term operational pressure and adds volatility to an already fragile earnings recovery path.
- Earnings Volatility & Negative Profitability: Quarterly results show extreme volatility, swinging from a $175M profit in Q1 2025 to an $892M loss in Q3 2025. The trailing net margin is -2.46% and ROE is -7.37%, indicating the company is currently destroying shareholder value, with earnings visibility extremely low.
LYB Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 1-year price change of +35.66% and a 6-month surge of +64.15%. With a current price of $73.72, it is trading near the top of its 52-week range (41.58 - 83.94), approximately 76% of the way to its high, indicating strong momentum but also potential overextension after a significant run. Recent momentum is exceptionally strong and accelerating, with the stock up 9.43% over the past month and 51.34% over the past three months, far outpacing the S&P 500's returns of 0.46% and -2.1% over the same periods, respectively, signaling a powerful breakout from its prior trading range. Key technical support is at the 52-week low of $41.58, while immediate resistance is at the 52-week high of $83.94; a breakout above this level would confirm the bullish trend, whereas a failure could signal a consolidation phase. The stock's beta of 0.437 indicates it is significantly less volatile than the broader market, which is unusual for a cyclical chemicals name but may reflect its large-cap status and recent defensive price action relative to its own fundamentals.
Beta
0.44
0.44x market volatility
Max Drawdown
-44.8%
Largest decline past year
52-Week Range
$42-$84
Price range past year
Annual Return
+27.5%
Cumulative gain past year
| Period | LYB Return | S&P 500 |
|---|---|---|
| 1m | +1.3% | +4.9% |
| 3m | +40.9% | +0.6% |
| 6m | +59.7% | +5.1% |
| 1y | +27.5% | +28.8% |
| ytd | +65.0% | +1.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LYB Fundamental Analysis
The company's revenue trajectory reflects the severe industry downturn, with Q4 2025 revenue of $7.09 billion representing a -25.33% year-over-year decline, continuing a multi-quarter trend of contraction from $9.50 billion in Q4 2024. Profitability has been severely impacted, with the company reporting a net loss of -$140 million and a gross margin of only 6.49% in the latest quarter, a sharp compression from the 7.80% gross margin in Q4 2024; the quarterly trend shows extreme volatility, swinging from a $175 million profit in Q1 2025 to an $892 million loss in Q3 2025. The balance sheet shows a leveraged but liquid position, with a debt-to-equity ratio of 1.58 and a current ratio of 1.77, while trailing twelve-month free cash flow remains robust at $2.26 billion, providing a crucial cushion to navigate the downturn, fund the reduced dividend, and maintain financial flexibility despite the operating losses.
Quarterly Revenue
$7.1B
2025-12
Revenue YoY Growth
-0.25%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LYB Overvalued?
Given the company's negative net income and negative EBITDA in recent quarters, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.46, while the Enterprise Value-to-Sales (EV/Sales) is 1.15, indicating the market is valuing the company at a significant discount to its revenue base. Compared to typical industry averages for specialty chemicals (which often trade above 1.0x Sales), LYB's sub-0.5x PS ratio represents a substantial discount, likely reflecting the market's pessimism over cyclical trough margins and the sustainability of current revenue levels. Historically, the stock's own PS ratio has fluctuated widely, from above 3.5x during peak cycles in 2021-2022 to the current 0.46x; trading near the absolute bottom of its historical valuation band suggests the market is pricing in a deeply pessimistic scenario, offering a potential value opportunity if the chemical cycle shows any signs of inflection.
PE
-18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -25x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. LYB is currently unprofitable, with a net margin of -2.46% and a gross margin of just 6.49% in the latest quarter, indicating severe margin pressure. Revenue has contracted by -25.33% year-over-year, and quarterly earnings show extreme volatility, swinging by over $1 billion between quarters, making forecasting highly uncertain. While free cash flow remains robust at $2.26B TTM, the recent dividend cut signals management is conserving cash due to expectations of prolonged weakness. The debt-to-equity ratio of 1.58, while not crippling, adds financial risk if the downturn extends.
Market & Competitive Risks center on cyclicality and valuation. As a petrochemical producer, LYB's fortunes are tied to global industrial demand and commodity spreads, which are currently weak. The stock's low beta of 0.44 is unusual for a cyclical and may reflect its large-cap status, but it does not eliminate macro sensitivity. The primary valuation risk is that the current deep discount (PS of 0.46x) persists or worsens if the cycle trough is longer than anticipated. Competitive pressure remains high in a commoditized industry, and recent geopolitical events disrupting naphtha supply, as per news, add a new layer of input cost volatility.
Worst-Case Scenario involves a prolonged global industrial recession combined with sustained high feedstock costs from Middle East disruptions. This could lead to consecutive quarters of significant losses, a credit rating downgrade due to elevated leverage, and a suspension of the already-reduced dividend. In this adverse scenario, the stock could re-test its 52-week low of $41.58, representing a potential downside of approximately -44% from the current price of $73.72. The analyst low target of ~$60.75, based on a $4.05 EPS estimate, suggests a more moderate but still significant bear-case downside of -18%.